A Phase I, randomized, double-blind, multi-centre, placebo-controlled, dose-escalation study to evaluate the safety, reactogenicity and immunogenicity of AstriVax’ investigational vaccine for the prevention of yellow fever (AVX70120), and of AstriVax’ investigational vaccine for the prevention of rabies (AVX70481), in healthy adults aged 18 to 40 years.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511194-29-00

Acronym

AVX1248-101

Enrollment

144

Registered

2024-06-13

Start date

2024-06-16

Completion date

Unknown

Last updated

2025-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rabies, Yellow fever

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Belgium

None listed

Source: EU CTIS · Data processed: Feb 4, 2026